Patch containing rivastigmine

US9585862B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9585862-B2
Application numberUS-201214118985-A
CountryUS
Kind codeB2
Filing dateMay 21, 2012
Priority dateMay 20, 2011
Publication dateMar 7, 2017
Grant dateMar 7, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.

First claim

Opening claim text (preview).

What is claimed is: 1. A rivastigmine-containing patch, comprising: (a) a drug-containing adhesive layer comprising rivastigmine free base, a copolymer of butyl methacrylate and methyl methacrylate, and an adhesive; and (b) a layer for adhering to the skin comprising a silicon adhesive, wherein the adhesive in the drug-containing adhesive layer is a random copolymer of 58 to 66 parts by weight of 2-ethylhexyl acrylate, 28 to 36 parts by weight of methyl acrylate and 4 to 8 parts by weight of acrylic acid, and wherein the drug-containing adhesive layer and the layer for adhering to the skin do not contain tocopherol. 2. The rivastigmine-containing patch of claim 1 , wherein the adhesive in the drug-containing adhesive layer has a solids content of 36.5%, a Brookfield viscosity value of 8000 mPa·s, a density of 0.92 g/ml, and a solvent composition comprising 87% ethyl acetate and 13% hexane. 3. The rivastigmine-containing patch of claim 1 , wherein the copolymer of butyl methacrylate and methyl methacrylate is a random copolymer thereof, and has a weight average molecular weight of 130,000 g/mol to 170,000 g/mol. 4. The rivastigmine-containing patch of claim 3 , wherein the copolymer of butyl methacrylate and methyl methacrylate has a weight average molecular weight of about 150,000 g/mol. 5. The rivastigmine-containing patch of claim 1 , wherein the silicon adhesive is trimethylated silica treated with dimethyl siloxane. 6. The rivastigmine-containing patch of claim 5 , wherein the silicon adhesive has a viscosity of 1200 mPa·s, a solid content of 60%, and a peel adhesion value of 700 g/cm. 7. The rivastigmine-containing patch of claim 6 , wherein the silicon adhesive is used in an amount of 27 mg/10 cm 2 to 33 mg/10 cm 2 based on the dry weight of the layer for adhering to the skin. 8. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 1 is packaged by nitrogen filling. 9. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 3 is packaged by nitrogen filling. 10. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 5 is packaged by nitrogen filling. 11. A product comprising a rivastigmine-containing patch, wherein the rivastigmine-containing patch of claim 7 is packaged by nitrogen filling. 12. The rivastigmine-containing patch of claim 1 , wherein the adhesive in the drug-containing adhesive layer has a solids content of 36.5%, a Brookfield viscosity value of 8000 mPa·s, a density of 0.92 g/ml, and a solvent composition comprising 87% ethyl acetate and 13% hexane, wherein the copolymer of butyl methacrylate and methyl methacrylate is a random copolymer thereof, and has a weight average molecular weight of 130,000 g/mol to 170,000 g/mol, and wherein the silicon adhesive is trimethylated silica treated with dimethyl siloxane. 13. The rivastigmine-containing patch of claim 12 , wherein the silicon adhesive has a viscosity of 1200 mPa·s, a solid content of 60%, and a peel adhesion value of 700 g/cm. 14. The rivastigmine-containing patch of claim 12 , wherein the silicon adhesive is used in an amount of 27 mg/10 cm 2 to 33 mg/10 cm 2 based on the dry weight of the layer for adhering to the skin.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Adhesives · CPC title

  • of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title

  • A61K31/325Primary

    Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145) · CPC title

  • Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9585862B2 cover?
The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.
Who is the assignee on this patent?
Hwang Yong-Youn, Choi Won-Jae, Kim Jae-Sun, and 5 more
What technology area does this patent fall under?
Primary CPC classification A61K31/325. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).